v3.25.4
Segments - Schedule of Consolidated Condensed Financial Statements (Details) - Operating Segments [Member] - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Schedule of Consolidated Condensed Financial Statements [Line Items]        
Government grant revenue $ 75,000 $ 100,000
Operating expenses:        
Research personnel compensation costs, including stock-based compensation 287,000 380,000 945,000 1,198,000
CRO and regulatory costs 315,000 315,000 15,000
Administrative personnel compensation costs, including stock-based compensation 4,125,000 302,000 4,861,000 1,014,000
Rent and office costs 97,000 34,000 415,000 196,000
Legal and accounting costs 976,000 426,000 1,625,000 1,018,000
Transaction costs 15,060,000 15,060,000
Other income (expense) [1] 848,000 36,000 915,000 77,000
Total segment expenses 21,708,000 1,178,000 24,136,000 3,518,000
Loss from operations (21,708,000) (1,103,000) (24,136,000) (3,418,000)
Other income (expense)    
Gain (loss) on change in the fair value of related party convertible debt 258,000 (319,000) (52,000) (427,000)
Gain on change in the fair value of warrant liabilities 884,000 884,000
Loss on change in the fair value of digital assets (28,000) (28,000)
Interest expense (169,000) (1,073,000) (2,496,000) (3,138,000)
Financing costs (1,443) (1,443,000)
Other income 15,000 (1,000) 15,000 5,000
Total other expense, net (484,000) (1,394,000) (3,210,000) (3,560,000)
Net loss and comprehensive loss $ (22,192,000) $ (2,497,000) $ (27,256,000) $ (6,978,000)
[1] Other expenses includes small balances of research materials and supplies along with insurance costs and other third party service providers.